Evidence map›Paper›PMID 18990943›Full record

ArticleInternational journal of nanomedicine2008

Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells.

Bao-An Chen, Yong-Yuan Dai, Xue-Mei Wang, Ren-Yun Zhang, Wen-Lin Xu, Hui-Ling Shen, Feng Gao, Qian Sun, Xiao-Jing Deng, Jia-Hua Ding and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. The effect of low concentrations of nanocrystalline cerium dioxide on the embryotoxicity of doxorubicin for fish.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Bao-An ChenDepartment of Hematology, The Affiliated Zhongda Hospital of Southeast University, Nanjing 210009, P.R. China. cba8888@hotmail.com
Yong-Yuan Dai
Xue-Mei Wang
Ren-Yun Zhang
Wen-Lin Xu
Hui-Ling Shen
Feng Gao
Qian Sun
Xiao-Jing Deng
Jia-Hua Ding
Chong Gao
Yun-Yu Sun
Jian Cheng
Jun Wang
Gang Zhao
Ning-Na Chen
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we have explored the possibility of the combination of the high reactivity of nano Fe3O4 or Au nanoparticles and daunomycin, one of the most important antitumor drugs in the treatment of acute leukemia clinically, to inhibit MDR of K562/A02 cells. Initially, to determine whether the magnetic nanoparticle Fe3O4 and Au can facilitate the anticancer drug to reverse the resistance of cancer cells, we have explored the cytotoxic effect of daunomycin (DNR) with and without the magnetic nano-Fe3O4 or nano-Au on K562 and K562/A02 cells by MTT assay. Besides, the intracellular DNR concentration and apoptosis of the K562/A02 cells was further investigated by flow cytometry and confocal fluorescence microscopic studies. The MDR1 gene expression of the K562/A02 cells was also studied by RT-PCR method. Our results indicate that 5.0 x 10(-7) M nano-Fe3O4 or 2.0 x 10(-8) M nano-Au is biocompatible and can apparently raise the intracellular DNR accumulation of the K562/A02 cells and increase the apoptosis of tumor cells. Moreover, our observations illustrate that although these two kinds of nanoparticles themselves could not lower the MDRI gene expression of the K562/A02 cells, yet they could degrade the MDR1 gene level when combining with anticancer drug DNR. This raises the possibility to combine the nano-Fe3O4 or nano-Au with DNR to reverse the drug resistance of K562/A02 cells, which could offer a new strategy for the promising efficient chemotherapy of the leukemia patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell SurvivalDaunorubicinDose-Response Relationship, DrugDrug SynergismFerric CompoundsGoldHumansK562 CellsLeukemiaNanoparticlesDaunorubicinFerric Compoundsferric oxideGold

Identifiers

PMID18990943
PMCPMC2626936
OpenAlexW2123799923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.